The U.S. Food and Drug Administration recently approved Ascelera (polidocanol) injections for the treatment of small varicose veins. Asclera has been approved to close spider veins, which are very small veins less than 1 millimeter in diameter, and reticular veins, which are 1-3 millimeters in diameter.
Polidocanol creates fibrosis, (the development of excess connective tissue in an organ or tissue as a reparative process), within the cell lining of blood vessels. This causes them to collapse, and eventually, the vein is then replaced by other types of tissue.
Adverse reactions to the drug include leakage, hematoma, bruising, irritation, discoloration, and pain at the injection site.
“Varicose veins are a common condition,” said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products at the FDA’s Center for Drug Evaluation and Research. “Asclera is indicated for the treatment of small types of varicose veins when the aim of treatment is to improve appearance.”
Varicose veins are swollen or abnormally twisted blood vessels that usually form in the legs, but they can also form in other places, such as the face. Heredity, age, and living in the western world are all known contributors to varicose veins. Women, especially if previously pregnant, are more likely to develop varicose veins.
Visit Novi Vein for more tips and information about varicose veins.
Tags: ascelera, FDA, novi vein, spider vein treatment, varicose vein treatment